EU averts delays to new drug approvals
This article was originally published in Scrip
A potential 30-day delay to the issuing of new EU marketing authorisations has been avoided after MEPs voted to shorten the statutory scrutiny period given to the European Parliament as part of the EU decision-making process.
You may also be interested in...
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.
Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.